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Abstract
Colorectal cancer is one of the commonest types of cancer and there is requirement for the identification of prognostic
biomarkers. In this study protein expression profiles have been established for colorectal cancer and normal colonic mucosa
by proteomics using a combination of two dimensional gel electrophoresis with fresh frozen sections of paired Dukes B
colorectal cancer and normal colorectal mucosa (n=28), gel image analysis and high performance liquid chromatography–
tandem mass spectrometry. Hierarchical cluster analysis and principal components analysis showed that the protein
expression profiles of colorectal cancer and normal colonic mucosa clustered into distinct patterns of protein expression.
Forty-five proteins were identified as showing at least 1.5 times increased expression in colorectal cancer and the identity of
these proteins was confirmed by liquid chromatography–tandem mass spectrometry. Fifteen proteins that showed
increased expression were validated by immunohistochemistry using a well characterised colorectal cancer tissue
microarray containing 515 primary colorectal cancer, 224 lymph node metastasis and 50 normal colonic mucosal samples.
The proteins that showed the greatest degree of overexpression in primary colorectal cancer compared with normal colonic
mucosa were heat shock protein 60 (p,0.001), S100A9 (p,0.001) and translationally controlled tumour protein (p,0.001).
Analysis of proteins individually identified 14-3-3b as a prognostic biomarker (x
2=6.218, p=0.013, HR=0.639, 95%CI 0.448–
0.913). Hierarchical cluster analysis identified distinct phenotypes associated with survival and a two-protein signature
consisting of 14-3-3b and aldehyde dehydrogenase 1 was identified as showing prognostic significance (x
2=7.306,
p=0.007, HR=0.504, 95%CI 0.303–0.838) and that remained independently prognostic (p=0.01, HR=0.416, 95%CI 0.208–
0.829) in a multivariate model.
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Introduction
In the western world colorectal cancer (CRC) is the third most
common type of cancer and the second most common cause of
cancer death [1]. Worldwide one million people each year will
develop CRC and the incidence of this tumour is increasing [1].
Most cases of CRC are sporadic resulting from the accumulation
of somatic genetic aberrations and are associated with a variety of
environmental risk factors [1,2]. The remaining proportion of
cases involve a familial genetic component. Numerous genetic
aberrations accumulate including the inactivation of the adeno-
matous polyposis coli tumour suppressor gene and activation of
oncogenes such as K-ras, deletion of chromosome 18q and
amplification of 20q [1,3]. Cumulatively these genetic changes
afford the tumour anti-apoptotic, pro-angiogenic and proliferative
properties. Recently it has been accepted that CRC is a genetically
heterogeneous disease and two distinct pathways of carcinogenesis
have been identified. Of sporadic CRC, 85% results from
chromosomal instability and the remaining 15% from microsat-
ellite instability [3]. Rather than occurring as a linear multistep
process, colorectal carcinogenesis is more likely to be the result of
the complex interplay between multiple mutational pathways.
This may partly explain the clinical heterogeneity of this disease
and the great difference seen in outcome between individual
patients [2]. This emphasises the clear requirement to have refined
methods of classifying and categorising colorectal cancer by
identifying and validating appropriate biomarkers.
Molecular biomarkers can be categorised by their ability to aid
prevention, promote early detection, establish prognosis and
predict response of patient to specific therapies [4,5]. The
discovery of biomarkers will also aid in the understanding of the
biological mechanisms underlying disease development and
progression. Whilst genomics including epigenomics and tran-
scriptomics have been influential in biomarker discovery, studying
genes and gene expression does not accurately reflect the amount
of protein expressed in the cell. Additionally proteins undergo
many post-translational modifications which can affect their
activation, interactions and function within a cell. Proteomics
which is the global study of proteins has a key role in the poten-
tial identification of tumour associated biomarkers [6,7]. The
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cancer has been extensively investigated and studies have included
biomarkers representing genes and proteins involved in many
aspects of tumour development and progression including tumour
invasion and metastasis, cell cycle regulation, growth factors and
apoptosis associated proteins [5,8–26].
In this study we have used comparative proteomic analysis (two
dimensional gel electrophoresis, image analysis of gels and mass
spectrometry) to identify proteins which are over-expressed in
colorectal cancer, compared with morphologically normal colo-
rectal mucosa. Overexpressed proteins have been validated
by immunohistochemistry using a large well characterised set of
colorectal cancers and a protein signature associated with pro-
gnosis identified.
Methods
Two dimensional (2D) gel electrophoresis
2D gel electrophoresis was performed using matched pairs of
fresh frozen Dukes’ B colon cancer and morphologically normal
colonic mucosa (caecum and ascending colon, n=15 and sigmoid
colon n=13) as previously described [20–22,27]. All cases were
selected from the Aberdeen colorectal tumour bank and the
clinicopathological details of the samples used for proteomics are
noted in Table 1. None of patients had received chemotherapy or
radiotherapy prior to surgery. On collection, both tumour and
normal colorectal mucosa were dissected from colorectal cancer
excision specimens within 30 minutes of surgical removal, and
immediately frozen in liquid nitrogen and stored at 280uC prior
to analysis.
Frozen sections (20 microns thickness, n=30) of each sample
were cut and solubilised in lysis buffer [27]. One section
(10 microns thickness) from each sample was stained with
haematoxylin and eosin and the morphological diagnosis con-
firmed by light microscopic examination. Following solubulisation,
the samples were centrifuged to remove insoluble cellular debris
Table 1. Clinico-pathological details of tumour samples used
for proteomic analysis.
Percent (number)
Sex
Male 61% (17)
Female 39% (11)
Age (mean:range) 73: 60–92
,70 36% (10)
$70 64% (18)
Tumour differentiation
Well/moderate 93% (26)
Poor 7% (2)
Extramural vascular invasion
Present 11% (3)
Absent 89% (25)
Tumour site
Proximal 43% (12)
Distal 57% (14)
Tumour stage
T3 82% (23)
T4 8% (5)
Nodal stage
N0 100% (28)
Mean lymph node yield 18 lymph nodes per case
Survival
Mean 76 months (95% CI 55–97 months)
22 of the tumours used for the proteomics studies are also represented in the
colorectal cancer TMA used for protein validation.
doi:10.1371/journal.pone.0027718.t001
Table 2. Details of the antibodies used in this study.
Antibody Supplier Antibody type Reference number (clone number) Optimal dilution
14-3-3b Sigma rabbit polyclonal HPA011212 1/500
Aldehyde dehydrogenase 1 (ALDH1) BD Biosciences mouse monoclonal 611194 (44) 1/1600
Enolase 1(ENO1) Abcam rabbit polyclonal ab85086 1/50
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) Abcam mouse monoclonal ab75479 (1A10A10) 1/2000
Glutathione peroxidase 1 (GPX1) Abcam rabbit polyclonal ab22604 1/1000
Heat shock protein 60 (HSP60) Abcam rabbit polyclonal ab46798 1/2000
Isocitrate dehydrogenase 1 (IDH1) Sigma rabbit polyclonal HPA035248 1/250
Lactate dehydrogenase B (LDHB) Abcam rabbit monoclonal ab53292 (EP1565Y) 1/800
Major vault protein (MVP) Abcam rabbit polyclonal ab97311 1/400
Nucleophosmin (NPM1) Sigma rabbit polyclonal HPA011384 1/800
Prohibitin (PHB) Abcam rabbit monoclonal ab75771 (EP2804Y) 1/100
Peptidylprolyl isomerase B (PPIB) Abcam rabbit polyclonal ab16045 1/1600
Peroxiredoxin 1 (PRDX1) Abcam rabbit polyclonal ab59538 1/400
S100A9 Abcam rabbit monoclonal ab92507 (EPR3555) 1/800
Translationally controlled tumour protein (TCTP) Abcam rabbit polyclonal ab37506 1/4000
MLH1 BD Pharmingen mouse monoclonal 554073 (G168-728) 1/100
MSH2 Merck mouse monoclonal NA27 (FE11) 1/50
doi:10.1371/journal.pone.0027718.t002
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duplicate for each sample using 13 cm pI3-10 non-linear
immobilon strips (GE Health Care, Little Chalfont, UK) with
proteins being separated according to charge (300 V, 6 mins,
3500 V, 90 min, 3500 V, 300 min), and subsequently molecular
weight (100 V, 25 mA per gel for 60 min). Following completion
of the electrophoresis, gels were stained with coomassie blue to
visualize proteins spots.
Gel imaging and analysis
The gels were then scanned to produce 256 grey scale 24 bit
images which were saved as TIFF files. The imaged gels were
analysed using Progenesis SameSpots software (Non-Linear
Dynamics, Newcastle-upon-Tyne, UK). All gel images were
imported into Progenesis SameSpots for analysis. Image quality
assessment was also done using the SameSpots software to ensure
all images were in the correct format for analysis and had no other
problems that could interfere with subsequent image analysis. All
gels were initially automatically aligned onto one reference gel
using the analysis software, then manually aligned to ensure
proper alignment of all gels, allowing all spots to be detected,
normalised and matched on all gels. Artefacts (e.g., dust particles
or streaks detected as protein spots) were removed by manual
editing. Reference image gels were created following gel alignment
using the analysis software. Once aligned, gels were automatically
analysed using the Progenesis SameSpots software. Gels were
separated into 2 groups as either tumour or normal gels. Statistical
analysis of protein expression levels were then determined for each
spot based on mean spot volume, and differences in protein
expression between tumour and normal gels were assessed by
ANOVA. Spots with a p#0.05 were selected for inclusion in the
results. Multivariate analysis was also done using Progenesis
SameSpots and both correlation analysis and principle components
analysis was performed on the imaged gels. Correlation analysis was
performed on log normalised spot expression levels to group spots
together according to similarities in their expression profiles.
Figure 1. Tumour and normal 2D gels. Representative reference 2D gels of normal colon (A) and colon tumour (C). These are the annotated
reference gels created by the Progenesis Same Spots gel image analysis software for the analysis of individual gels. The number of each spot is
assigned by the image analysis software. For easier visualisation of individual spots representative non-annotated 2D gels of normal colon and colon
tumour are shown in panels B and D respectively. The proteins which were validated by immunohistochemistry have been identified in D.
doi:10.1371/journal.pone.0027718.g001
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gelstoseparatethe gelsaccordingtoexpressionvariation,allowing a
graphical representation of the multidimensional data, clustered
into the two groups; tumour and normal. A final report showing all
analysed spots on the gel together with ANOVA values, ranks and
expression profiles for each spot based on the average normalised
volume for the groups was then produced.
Liquid chromatography–tandem mass spectrometry
Following 2D gel electrophoresis and image analysis of the gels
the protein spots of interest (those spots which were significantly
increased in the tumour samples) were excised from the gels and
proteins identified by liquid chromatography-tandem mass
spectrometry.
Proteins in the gel pieces were digested with trypsin (sequencing
grade, modified; Promega UK, Southampton, UK) using an
Investigator ProGest robotic workstation (Genomic Solutions Ltd.,
Huntingdon, UK). Briefly, proteins were reduced with DTT
(60uC, 20 min), S-alkylated with iodoacetamide (25uC, 10 min)
then digested with trypsin (37uC, 8 h). The resulting tryptic
peptide extract was dried by rotary evaporation (SC110 Speedvac;
Savant Instruments, Holbrook, NY, USA) and dissolved in 0.1%
formic acid for LC-MS/MS analysis.
Peptide solutions were analysed using an HCTultra PTM
Discovery System (Bruker Daltonics Ltd., Coventry, UK) coupled
to an UltiMate 3000 LC System (Dionex (UK) Ltd., Camberley,
Surrey, UK). Peptides were separated on a monolithic capillary
column (200 mm internal diameter 65 cm in length; Dionex).
Eluent A was 3% acetonitrile in water containing 0.05% formic
acid, eluent B 280% acetonitrile in water containing 0.04% formic
acid with a gradient of 3%–45% B in 12 minutes at a flow rate of
2.5 mL/min. Peptide fragment mass spectra were acquired in data-
dependent AutoMS(2) mode with a scan range of 300–1500 m/z, 3
averages, and up to 3 precursor ions selected from the MS scan
100–2200 m/z). Precursors wereactivelyexcluded withina 1.0 min
window, and all singly charged ions were excluded.
Peptide peaks were detected and deconvoluted automatically
using data analysis software (Bruker). Mass lists in the form of
Mascot generic files were created automatically and used as the
input for Mascot MS/MS Ions searches of the NCBInr database
using the Matrix Science web server (www.matrixscience.com).
The default search parameters used were: enzyme=trypsin,
maximum missed cleavages=1; fixed modifications=carbamido-
methyl (C); variable modifications=oxidation (M); peptide
tolerance 61.5 Da; MS/MS tolerance 60.5 Da; peptide
charge=2+ and 3+ and instrument=ESI-TRAP.
Both two dimensional gel electrophoresis and mass spectrom-
etry were carried out by the University of Aberdeen Proteome
facility (www.abdn.ac.uk/ims/proteomics/).
Development of colorectal cancer tissue microarray
A colorectal cancer tissue microarray was constructed containing
normal colon mucosa (n=50), primary (n=515) and metastatic
colorectal cancer (n=224) as previously described [28,29].
All cases were selected from the Aberdeen colorectal tumour
bank. In total, tumour samples from 515 patients were involved in
this study, in each case, a diagnosis of primary colorectal cancer
had been made, and the patients had undergone elective surgery
for primary colorectal cancer, in Aberdeen, between 1994 and
2007. 99 tumours were from the period 1994–1998, 199 tumours
were from 1999–2003 and 217 tumours were from the period
2004–2007. None of the patients had received any pre-operative
chemotherapy or radiotherapy. The data for the patients and their
tumours included in this study is detailed in supporting information
Table S1. The mean lymph node yield for all tumours in this study
was 13.4 lymph nodes per tumour and for node negative tumours
the mean lymph node yield was 14.4 (lymph node yield refers to the
total number of lymph nodes retrieved from each colorectal cancer
resection specimen). Survival information was available for all
patients and atthetime of censoringpatientoutcome datatherehad
been 237 (46%) deaths (all cause mortality). The mean patient
survival was 114 months (95% CI 105–122 months). The colorectal
cancer excision specimens were received fresh, opened above and
when appropriate below the tumour, washed in cold water and then
fixed in 10% neutral buffered formalin for at least 48 hours at room
temperature and representative blocks were embedded in wax.
Sections were stained with haematoxylin and eosin for histopath-
ological diagnosis and the tumours were reported according to The
Royal College of Pathologists guidelines which incorporate
guidance from TNM5 of the TNM staging system.
A colorectal cancer tissue microarray was constructed contain-
ing normal colon mucosa (n=50), primary (n=515) and
metastatic colorectal cancer (n=224). The metastases were all
from tumour involved lymph nodes of the Dukes C cases. Each
normal mucosal sample was acquired from at least 10 cm distant
from the tumour as previously described [28,29]. All the cases
were reviewed and areas of tissue to be sampled were first
identified and marked on the appropriate haematoxylin and eosin
stained slide by an expert consultant gastro-intestinal pathologist
(GIM). Two 1 mm cores were taken from these areas of the
corresponding wax embedded block using a Beecher Instruments
tissue microarrayer (Sun Prairie, WI, USA) and placed in a
recipient paraffin block. Following transfer, the recipient array
block was heated to 37uC, and a glass slide was used to carefully
press down the cores to ensure they were all at the same level
within the recipient wax block.
Immunohistochemistry
Immunohistochemistry for each antibody (Table 2) was
performed with the biotin free Dako Envision
TM system (Dako,
Ely, UK) using a Dako autostainer (Dako) as previously described
[28,30,31]. Sections of the tissue microarray were dewaxed in
xylene, rehydrated in alcohol and an antigen retrieval step
performed. This step consisted of microwaving the sections fully
immersed in 10 mM citrate buffer at pH6.0 for 20 minutes in an
800 W microwave oven operated at full power. The sections were
then allowed to cool to room temperature. The primary antibody
appropriately diluted (Table 2) in antibody diluent (Dako) was
Figure 2. Hierarchical cluster and principal components analyses of 2D gels. Representative hierarchical cluster analysis (A) and principal
components analysis (B) of normal and tumour gels. Both statistical methods show that the protein expression profiles determined by 2D gel
electrophoresis and gel image analysis are distinct in tumour samples compared with normal samples. The lower panel in each figure shows the
standardised expression profiles. The figures presented in figure 2 are ‘‘screen captures’’ of the output of analysis by the Progenesis SameSpots
software. Both figure 2A and figure 2B represents the results of the same experiment of one case (i.e. one pair of normal gels N1 and N2 and one pair
of tumour gels T1 and T2). The lower panel in each part of the figure shows the standardised expression profile and represents proteins of distinct
expression plotted vertically with lines ’’connecting’’ the corresponding proteins in each gel. The coloured spots represent interactive spots placed by
the software for the user to access each data set and are positioned arbitrarily by the software on the screen.
doi:10.1371/journal.pone.0027718.g002
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(Dako) with subsequent peroxidase blocking for 5 minutes (Dako).
This was followed by a single 2 minute buffer wash after which
pre-diluted peroxidase-polymer labelled goat anti-mouse/rabbit
secondary antibody (Envision
TM, Dako) was applied for 30 min-
utes at room temperature, followed by further washing with buffer
to remove unbound antibody. Sites of peroxidase activity were
then demonstrated with diaminobenzidine as the chromogen
applied for three successive 5 minute periods. Finally sections were
washed in water, lightly counterstained with haematoxylin,
dehydrated and mounted. Omitting the primary antibody from
the immunohistochemical procedure and replacing it either with
antibody diluent or non-immune rabbit serum as appropriate
acted as negative controls. Positive controls were tissues known to
express the individual protein.
The sections were evaluated by light microscopic examination
and the intensity of immunostaining in each core assessed
independently by two investigator (DO’D and GIM) using a
scoring system previously described for the assessment of protein
expression in tumour microarrays [28–31]. The intensity of
immunostaining in each core was scored as negative, weak,
moderate or strong. The subcellular localisation (either nuclear or
cytoplasmic) of the immunostaining was also assessed. Variation in
immunostaining between cores of each case was not identified.
Any discrepancies in the assessment of the tissue cores between the
two observers were resolved by simultaneous microscopic re-
evaluation.
Assessment of microsatellite instability status
Microsatellite instability status (MSI) was assessed by immuno-
histochemistry using antibodies to MLH1 and MSH2 (Table 2) as
described previously [30].
Statistics
Statistical analysis of the immunohistochemical data including
the Mann-Whitney U test, Wilcoxon signed rank test, chi-squared
test, hierarchical cluster analysis, Kaplan-Meier survival analysis,
log-rank test and Cox multi-variate analysis (variables entered as
categorical variables) including the calculation of hazard ratios and
95% CIs were performed using PASW v18.0.2 for Windows
XP
TM (SPSS UK, Ltd, Woking, UK). The log rank test was used
to determine survival differences between individual groups. A
probability value of p#0.05 was regarded as significant. To
explore the influence of different cut-off points in relation to
survival the immunohistochemical scores for each marker were
dichotomized. The groups that were analysed were negative versus
any positive staining, negative and weak staining versus moderate
and strong staining and negative, weak and moderate staining
versus strong staining. Hierarchical cluster analysis was carried out
using the furthest neighbour method with the square Euclidean
distance as the cluster measure and cluster analysis was performed
without any transformation of the data or imputation of missing
values [18,19].
Ethics
The project had the approval of The North of Scotland
Research Ethics Committee (ref. no. 08/S0801/81). Written
Figure 3. Immunohistochemistry photomicrographs. Photomi-
crographs of the immunohistochemical localisation of individual
proteins in normal colon, primary colorectal cancer and lymph node
metastasis.
doi:10.1371/journal.pone.0027718.g003
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27718Figure 4. Frequency expression of individual proteins in normal colon, colorectal cancer and metastatic colorectal cancer. Frequency of
expression as evaluated immunohistochemically of individual proteins in A. normal colon, B, primary colorectal cancer and C. lymph node metastasis.
doi:10.1371/journal.pone.0027718.g004
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fresh samples of tissue for the proteomics component of the study.
The research ethics committee waived the requirement for written
consent for the retrospective tissue samples included in the
colorectal cancer tissue microarray.
Results
Proteomics
In total more than 1200 individual protein spots were resolved
following separation by 2D gel electrophoresis and image analysis in
normal colonic mucosa and colon tumours (Figure 1). Hierarchical
cluster analysis and principle components analysis showed the
separation of the proteins into two distinct groups- normal and
tumour (Figure 2). The study included both proximal and distal
colon tumours and neither cluster nor principle components analysis
showed that there was any difference in protein expression profiles
between tumour and normal mucosa in these anatomical locations.
Proteins showing greater than and equal to 1.5 fold increased
expression in tumour samples are summarised in supporting
information Table S2. The identity of these proteins was mostly
confirmed by liquid chromatography–tandem mass spectrometry.
For each protein multiple peptides with a high statistical probability
(p,0.05) of matchestotherelevant proteinwereanalysedto confirm
identity. Details of mass spectrometric identification of proteins are
shown in supporting information Table S3.
Immunohistochemistry
Fifteen proteins were selected for immunohistochemical valida-
tion. The criteria for the selection of the proteins included the
degree of overexpression in colorectal cancer, exclusion of known
structural e.g. actin and serum proteins e.g.haemoglobin and the
Table 3. Comparison of protein expression in normal colonic mucosa, primary colorectal cancer and lymph node metastasis.
Protein
Immunoreactivity
(p value, normal v primary tumour)
Change in expression
in tumour
Immunoreactivity (p value,
primary Dukes C tumour v
lymph node metastasis)
Change in expression
in lymph node
14-3-3b 0.243 - 0.003 Q
ALDH1 0.328 - 0.005 Q
ENO1 0.015 q 0.047 Q
GAPDHc 0.043 q 0.074 -
GAPDHn 0.168 - 0.405 -
GPX1 0.053 q 0.277 -
HSP 60 ,0.001 q 0.005 Q
IDH1 0.001 Q 0.02 Q
LDHB 0.015 Q 0.021 Q
MVP 0.009 q 0.877 -
NPM1 0.003 q 0.02 Q
PHB 0.056 - 0.002 Q
PPIB 0.001 q 0.43 -
PRDX1 0.021 q 0.003 Q
S100A9 ,0.001 q 0.009 Q
TCTP ,0.001 q 0.74 -
Evaluation of normal colonic epithelium versus primary tumour samples for immunoreactivity (Mann-Whitney U test, q=increased in tumour, Q=decreased in
tumour, -=no change between tumour and normal) and evaluation of primary Dukes C colorectal tumour samples and their corresponding metastasis samples for
immunoreactivity (Wilcoxon signed rank sum test, q=increased in lymph node metastasis, Q=decreased in lymph node metastasis, -=no change between primary
and metastatic tumour).
doi:10.1371/journal.pone.0027718.t003
Table 4. The relationship of protein expression in Dukes A,
Dukes B and Dukes C colorectal cancers (Mann-Whitney U
test).
Protein
Dukes A v Dukes B
(p value)
Dukes B v Dukes C
(p value)
14-3-3b ,0.001 ,0.001
ALDH1 ,0.001 0.001
ENO1 0.001 0.960
GAPDHc 0.009 0.002
GAPDHn 0.001 0.443
GPX1 0.03 0.028
HSP 60 0.001 0.531
IDH1 ,0.001 0.583
LDHB 0.714 0.413
MVP 0.02 0.004
NPM1 0.506 0.943
PHB 0.03 0.360
PPIB 0.517 0.795
PRDX1 0.053 0.521
S100A9s ,0.001 0.452
S100A9t 0.474 0.094
TCTP 0.562 0.014
doi:10.1371/journal.pone.0027718.t004
Colorectal Cancer Proteomics
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27718Figure 5. Frequency expression of individual proteins in specific Dukes stages of colorectal cancer. Frequency of expression of individual
proteins as evaluated immunohistochemically in A. Dukes A colorectal cancer, B. Dukes B colorectal cancer and C. Dukes C colorectal cancer.
doi:10.1371/journal.pone.0027718.g005
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Pathological parameter
Tumour site Tumour differentiation EMVI MSI status T stage N stage Dukes stage
Protein x
2 p value x
2 p value x
2 pv a l u e x
2 p value x
2 p value x
2 p value x
2 p value
14-3-3b 8.306 0.217 2.887 0.409 4.806 0.187 22.441 ,0.001 18.234 0.033 10.146 0.119 35.370 ,0.001
ALDH1 12.495 0.052 5.318 0.15 0.509 0.917 7.090 0.069 21.108 0.012 8.858 0.182 21.859 0.001
ENO1 14.941 0.021 0.021 0.999 0.966 0.809 7.171. 0.067 23.055 0.006 8.895 0.18 26.217 ,0.001
GAPDHc 5.225 0.515 5.817 0.121 3.238 0.356 2.969 0.396 12.92 0.166 11.138 0.084 17.321 0.008
GAPDHn 20.89 0.002 13.442 0.004 3.298 0.348 12.516 0.006 17.227 0.045 7.721 0.259 17.678 0.007
GPX1 4.841 0.564 1.018 0.797 6.848 0.077 4.185 0.282 6.027 0.737 5.198 0.519 7.733 0.258
HSP 60 12.318 0.055 3.965 0.265 4.826 0.185 27.663 ,0.001 14.326 0.111 10.191 0.117 14.548 0.024
IDH1 7.912 0.245 12.244 0.007 0.464 0.927 47.733 ,0.001 14.483 0.106 5.444 0.488 11.467 0.075
LDHB 6.046 0.418 0.015 0.999 7.529 0.057 9.597 0.022 10.23 0.332 5.679 0.46 5.53 0.478
MVP 7.86 0.249 27.276 ,0.001 0.935 0.817 21.393 ,0.001 12.053 0.21 23.198 0.001 21.669 0.001
NPM1 1.384 0.501 0.155 0.694 0.907 0.341 2.134 0.144 1.047 0.79 1.953 0.377 0.427 0.808
PHB 15.693 0.016 6.414 0.093 4.562 0.207 21.392 ,0.001 19.301 0.023 5.072 0.535 9.468 0.149
PPIB 8.814 0.184 3.615 0.306 1.439 0.696 4.628 0.201 10.672 0.299 1.789 0.938 3.062 0.801
PRDX1 6.35 0.385 8.636 0.035 4.572 0.206 9.808 0.020 8.683 0.467 6.043 0.418 6.141 0.408
S100A9s 7.703 0.261 9.12 0.028 5.33 0.149 5.601 0.133 16.4 0.059 5.691 0.459 19.979 0.003
S100A9t 2.91 0.82 3.869 0.276 2.834 0.418 4.224 0.238 13.741 0.132 7.133 0.309 6.566 0.363
TCTP 14.924 0.021 5.115 0.164 2.569 0.463 14.457 0.002 5.86 0.754 12.866 0.045 16.723 0.01
Significant values are highlighted in bold.
doi:10.1371/journal.pone.0027718.t005
Table 6. The relationship of individual protein expression with survival (log rank test) using different cut-off points for the
immunohistochemical data.
Cut-off point
Negative v weak/moderate/strong
Negative and weak v moderate and
strong Negative, weak and moderate v strong
Protein x
2 p value x
2 p value x
2 p value
14-3-3b 6.218 0.013 0.069 0.793 0.005 0.942
ALDH1 1.478 0.224 0.367 0.545 0.165 0.685
ENO1 1.758 0.185 2.323 0.127 0.47 0.493
GAPDHc 0.858 0.354 0.002 0.965 0.105 0.746
GAPDHn 1.653 0.198 0.10 0.922 0.490 0.484
GPX1 0.021 0.886 0.689 0.406 0.167 0.683
HSP 60 0.315 0.575 1.303 0.254 2.1 0.147
IDH1 0.094 0.759 6.415 0.011 4.636 0.031
LDHB 0.403 0.525 5.763 0.016 2.979 0.084
MVP 0.523 0.470 0.120 0.729 3.795 0.051
NPM1 - - - - 0.009 0.923
PHB 7.883 0.005 0.237 0.627 0.249 0.617
PPIB 0.386 0.535 1.563 0.211 0.969 0.325
PRDX1 1.669 0.196 0.813 0.367 1.207 0.272
S100A9s 0.016 0.9 0.051 0.821 1.021 0.312
S100A9t 0.027 0.869 0.263 0.608 1.013 0.314
TCTP 0.341 0.559 3.895 0.048 3.776 0.052
Significant values are highlighted in bold.
doi:10.1371/journal.pone.0027718.t006
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formalin fixed wax embedded tissue.
All the proteins showed tumour cell staining and except
nucleophosmin (NPM1) showed cytoplasmic staining (Figure 3).
NPM1 showed exclusively nuclear staining while glyceraldehyde 3
phosphate dehydrogenase (GAPDH) showed both nuclear and
cytoplasmic staining and these two sub-cellular localisations have
been assessed separately for this protein. S100A9 showed both
variable tumour cell staining (S100A9t) and variable stromal cell
staining (S100A9s) and these two cellular localisations of this
protein have been evaluated separately. The proteins that most
frequently showed strong tumour cell immunoreactivity in primary
colorectal cancer were NPM1 (99.6%), major vault protein
(MVP, 81.1%) and prohibitin (PHB, 75.6%) while in lymph node
metastasis those proteins which showed the most frequent strong
tumour cell immunoreactivity were NPM1 (95.8%), MVP (74.5%)
and heat shock protein 60 (HSP60, 63.9%) (Figure 4). In normal
colon the proteins that showed the highest frequency of strong
epithelial cell immunoreactivity were NPM1 (99.6%), isocitrate
dehydrogenase 1 (IDH1, 93%) and lactate dehydrogenase B
(LDHB, 82.1%) (Figure 4).
The proteins that showed the greatest degree of overexpression
in primary colorectal cancer compared with normal colonic
mucosa were HSP60 (p,0.001), S100A9 (p,0.001) and translat-
inally controlled tumour protein (TCTP, p,0.001, Table 3), while
for Dukes C cancers no proteins showed increased immunoreac-
tivity in the lymph node metastasis compared with the corre-
sponding primary colorectal cancers and the proteins that showed
the greatest decrease in expression in lymph node metastasis were
PHB (p=0.002), peroxiredoxin (PRDX1, p=0.003) and HSP60
(p=0.005, Table 3). The relationship of protein expression with
individual Dukes stages is shown in Table 4 and Figure 5.
Comparisons of the expression of individual proteins and
clinico-pathological parameters are detailed in Table 5. Several
of the proteins showed a highly significant association with
microsatellite instability status including 14-3-3b (x
2=22.441,
p,0.001), HSP60 (x
2=27.663, p,0.001) and IDH1 (x
2=47.733,
p,0.001).
Survival analysis
Analysis of individual markers. The relationship of the
expression of individual proteins and survival was investigated
using different cut-off points (negative v positive, negative/weak
positive v moderate/strong and negative/weak/moderate v
strong) and is summarised in Table 6 and Figure 6. 14-3-3b was
identified as showing prognostic significance (x
2=6.218,
p=0.013, hazard ratio (HR)=0.639, 95% confidence interval
(CI) 0.448–0.913) when negative tumours were compared with
tumours showing any degree of 14-3-3b immunoreactivity
(Figure 6A). Tumours showing an absence of 14-3-3b
immunoreactivity were associated with a better prognosis. For
patients with 14-3-3b negative tumours (n=104, number of
deaths=36) the mean survival was 129 months (95%CI 113–145
months) and for patients with positive tumours (n=398; number
of deaths=194) the mean survival was 107 months (95% CI
98–117 months). This was prognostically significant (p=0.03,
HR=0.588, 95%CI 0.361–0.958) in a multivariate model
containing all variables (Dukes stage, EMVI, tumour site, patient
age, patient sex, expression of individual proteins). The other
significant variables were Dukes stage (p,0.001, HR=0.491,
95%CI 0.357–0.714), age (p,0.001, HR=0.470, 95%CI 0.343–
0.645) and extramural vascular invasion (EMVI, p,0.001,
HR=0.467, 95%CI 0.338–0.644). Although PHB expression
(positive v negative PHB immunoreactivity) was also noted to have
a highly significant association with survival (x
2=7.883, p=0.005,
HR=3.311, 95% CI 1.359–8.064) only 6 patients were in the
PHB negative group (Figure 6B). Other protein which showed a
significant relationship with survival using different cut off points
were IDH1, LDHB, TCTP and MVP (Table 6 and Figure 6C–
6G).
Hierarchical cluster analysis and identification of
prognostic protein signature. Hierarchical cluster analysis
was also used as an exploratory statistical tool to examine the
overall relationship of marker expression with outcome and based
on this identify a protein signature associated with prognosis. A
range of cluster solutions (number of clusters) was investigated to
determine the optimum number of clusters that produced groups
with different outcomes. Clustering the data into ten clusters was
identified as the optimum number of clusters for analysis in
relation to the most prognostically significant groups (supporting
information Table S4, Figure 6H and Figure 7). These 10 clusters
were then combined into two prognostic groups; a good prognosis
group (cluster 1) and a poor prognosis group (cluster groups 2–10)
(Figure 6I). The good prognosis group (mean survival=157
months 95% CI 135–177 months, n=39, number of deaths=8)
had a significantly better survival (x
2=8.144, p=0.004, HR=
0.373, 95% CI 0.179–0.757) than the poor prognosis group (mean
survival=106 months, 95%CI 1-2-119 months, n=392, number
of deaths=183).
Further analysis of the data based on the distribution of proteins
in these cluster groups identified a two protein signature of 14-3-
3b and aldehyde dehydrogenase 1 (ALDH1) that showed greater
prognostic significance (x
2=7.306, p=0.007, HR=0.504, 95%CI
0.303–0.838) than 14-3-3b alone (Figure 6J). Those tumours that
were both 14-3-3b and ALDH1 negative had a better prognosis
than tumours showing either 14-3-3b or ALDH1 positivity. For
patients with 14-3-3 b/ALDH1 negative tumours (n=59, number
of deaths=16) the mean survival (estimate) was 109 months
(95%CI 95–123 months) and for patients with either or both
14-3-3 b and ALDH1 positive tumours (n=426, number of
deaths=206) the mean survival was 110 months (95% CI 101–
119 months). This was also prognostically significant (p=0.01,
HR=0.416, 95%CI 0.208–0.829) in a regression model contain-
ing all variables (Dukes stage, EMVI, tumour site, tumour
differentiation, patient age, patient sex, 14-3-3 b/ALDH1
expression). The other significant variables were Dukes stage
(p,0.001, HR=0.492, 95%CI=0.338–0.715), age (p,0.001,
HR=0.463, 95% CI 0.337–0.636) and EMVI (p,0.001,
HR=0.484, 95%CI 0.351–0.668).
Figure 6. Survival curves of marker proteins. The relationship of individual proteins evaluated by immunohistochemistry with survival with
different cut-off points. A. 14-3-3b (positive v negative immunoreactivity), B. PHB (positive v negative immunoreactivity), C. IDH1 (negative/weak
immunoreactivity v moderate/strong immunoreactivity), D. LDHB (negative/weak immunoreactivity v moderate/strong immunoreactivity), E. TCTP
(negative/weak immunoreactivity v moderate/strong immunoreactivity), F. IDH1 (negative/weak/moderate immunoreactivity v strong immunore-
activity), G. MVP (negative/weak/moderate immunoreactivity v strong immunoreactivity), H. survival in each of 10 clusters identified by hierarchical
cluster analysis (each cluster is numerically identified and corresponds to the clusters that are identified in the cluster analysis panel of Figure 7), I.
survival in 2 clusters- cluster 1 and clusters 2–10 combined and J. two protein signature of 14-3-3b and ALDH1 showing that double negative
tumours have a significantly better outcome.
doi:10.1371/journal.pone.0027718.g006
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This study has performed a comprehensive proteomic analysis
and immunohistochemical validation of protein expression in a
large well characterised series of colorectal cancers (n=515). The
overexpression of individual proteins in colorectal cancer has been
established and a two protein signature associated with prognosis
identified.
There have been a number of proteomic studies performed on
colorectal cancer. A range of proteomics technology have been
utilised although the predominant technologies have been 2D gel
electrophoresis combined with mass spectrometry which are both
robust and well established technologies [32–42]. In most of those
proteomics studies usually only a small number (often less than 10)
of tissue samples have been included and some of the tissue
samples included in these studies have little or no clinico-patho
logical information possibly as a consequence of the samples
having been procured from a third party tissue or tumour bank. In
the absence of the clinico-pathological information interpretation
of the proteomic studies is more difficult. Similarly when a
validation component has been incorporated into those studies
these have often been limited by the number of samples included
in this part of individual investigations [41].
Proteomics showed that the most significantly overexpressed in
protein in colorectal cancer was the beta sub-unit of 14-3-3. The
14-3-3 proteins are phosphoserine/phosphothreonine binding
proteins composed of seven subunits which can both homo- and
heterodimerise [43–45]. These proteins are involved in the
regulation of multiple cellular signalling pathways including cell
cycle regulation, apoptosis, metabolism, transcription and protein
trafficking many of them in a phosphorylation dependent manner.
They are known to interact with pathways e.g. ras/raf and AKT/
mTOR pathways involved in tumourigenesis [45]. Other proteins
that were shown to be ovexpressed in CRC included the metabolic
enzymes (enolase 1 (ENO1), GAPDH, IDH1 and LDHB) involved
in pathways of glucose metabolism. Some of these proteins have
previously been noted to have increased expression in CRC by
proteomics [41] and highlights the increased/altered glucose
metabolism occurring in tumours [46].
The selection of proteins to be validated by immunohistochem-
istry was based on the degree of overexpression identified by the
proteomic studies with the exclusion of structural and serum
proteins and the availability of well characterised antibodies
already shown to be effective on formalin fixed wax embedded
tissue. The presence of 14-3-3b in colorectal cancer samples was
confirmed by immunohistochemistry with a cytoplasmic location
in tumour cells although its overexpression was not substantiated
by immunohistochemistry. However, the comparative evaluation
of proteins is based on different technologies. 2D gel electropho-
resis and images analysis identified and compares average spot
volumes in a gel while immunohistochemistry identifies cellular/
subcellular location of the protein combined with a semi-
quantitative assessment of the intensity of immunoreactivity of
the individual protein.
Two methods were used to explore the relationship of protein
expression with clinico-pathological factors and outcome. Each
Figure 7. Hierarchical cluster analysis of immunohistochemical
marker proteins. Graphical representation of the immunohistochem-
istry marker data is shown in the middle panel. The right hand panel
shows the results of the hierarchical cluster analysis presented as a
dendrogram with 10 individual clusters identified. The left hand panel
shows an expanded segment of the graphical representation. Proteins
are represented in columns and cases in rows.
doi:10.1371/journal.pone.0027718.g007
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univariate survival analysis while hierarchical cluster analysis was
performed to explore the overall relationship of marker expression,
clinicopathological factors and survival to provide a more detailed
understanding of that relationship.
The relation of individual proteins with survival in univariate
analysis was explored in the data set using different cut-off points to
dichotomize the data. The most robust cut-off point would appear
to be the division between absence and presence of immunoreac-
tivity when considered on the likelihood of reproducibility. On that
basis 14-3-3b was associated with prognosis with absent 14-3-3b
being associated with a better prognosis. The use of other cut-off
points highlight otherpotentialmarkers (IDH1,LDHB,MVP,PHB
and TCTP) however those cut-off points i.e. a division between
weak and moderate staining or a division between moderate and
strong staining are potentially much less robust in practice than a
cut-off between negative and positive.
Hierarchical cluster analysis which has been widely applied to
gene expression data sets but rarely immunohistochemical data
[18,19] identified multiple clusters and based on cluster membership
the combination of two proteins were identified namely 14-3-3b and
ALDH1 as prognostically significant. It is interesting to note that
ALDH1 has been proposed as a stem cells marker and has recently
been suggested to be a marker of colon cancer stem cell [47].
The colorectal cancer tissue microarray was also specifically
designed to include lymph node metastasis from those primary
tumours with lymph node metastasis. This is a particular strength
of the design of this tumour microarray and allowed a direct
comparison of the phenotype of primary tumours and their
synchronous lymph node metastasis. This is important for example
as treatment in the adjuvant setting is targeted at metastatic
disease and it is an assumption that the phenotype of primary
tumours necessarily reflects the phenotype of secondary tumours
[48,49]. Expression in the metastasis is likely to be influence by the
microenvironmental setting in which the metastasis develop [47].
Most of the proteins examined showed decreased expression in the
metastasis compared with their corresponding primary tumours
indicating that further deregulation of protein expression is
occurring in the lymph node metastasis. Most notably 14-3-3b,
ALDH1 and PHB showed significant decreases in expression in
lymph node metastasis compared with primary tumours providing
evidence for further dysregulation of protein expression in
metastasis [47].
In summary this study has performed a comprehensive
proteomics analysis of colorectal cancer and identified proteins
that are overexpressed in colorectal cancer. Validation has been
performed using immunohistochemistry and a two-protein
signature associated with prognosis identified.
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